Format Comparison
Semaglutide Oral vs Injection: Format Comparison
Oral and injectable semaglutide are the same molecule with very different pharmacokinetics. Choice depends on tolerance for daily administration, GI observed effects in study models, and target endpoint.
Side-by-side comparison
| Attribute | Semaglutide (Oral) | Semaglutide (Subcutaneous) |
|---|---|---|
| Bioavailability | ~1 percent | ~89 percent |
| Mean metabolic research at 68 weeks | ~15 percent (PIONEER 4 to 6) | ~17 percent (STEP 1) |
| HbA1c reduction in T2D | ~1.0 to 1.3 percent | ~1.4 to 1.8 percent |
| GI observed effects in study models | Comparable, nausea most common | Comparable, nausea most common |
Key differences
- ·Oral semaglutide bioavailability is roughly 1 percent, requiring SNAC absorption enhancer
- ·Head to head, injectable produces larger metabolic research in published trials
Research summary
PIONEER trials evaluated oral semaglutide in T2D and obesity. SUSTAIN and STEP trials established the injectable benchmark. Injectable produces modestly greater weight and glycaemic outcomes, oral offers convenience for needle-averse users.